The impact of fibroblast growth factor-23 on the cardiovascular system in chronic kidney disease

References

• Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17(7):2034-47
   PubMed Web of Science ®Google Scholar
• Chronic Kidney Disease Prognosis C. Matsushita K, van der Velde M, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375(9731):2073-81
   PubMed Web of Science ®Google Scholar
• US Renal Data System.USRDS 2012. Annual Data Report
   Google Scholar
• Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382(9889):339-52
   PubMed Web of Science ®Google Scholar
• Kennedy R, Case C, Fathi R, et al. Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease? Am J Med 2001;110(3):198-204
   PubMed Web of Science ®Google Scholar
• Kaisar M, Isbel N, Johnson DW. Cardiovascular disease in patients with chronic kidney disease. A clinical review. Minerva Urol Nefrol 2007;59(3):281-97
   PubMedGoogle Scholar
• Ix JH, De Boer IH, Peralta CA, et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009;4(3):609-15
   PubMed Web of Science ®Google Scholar
• Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012;82(7):737-47
   PubMed Web of Science ®Google Scholar
• Smith ER, McMahon LP, Holt SG. Fibroblast growth factor 23. Ann Clin Biochem 2014;51(Pt 2):203-27
   PubMed Web of Science ®Google Scholar
• Krajisnik T, Bjorklund P, Marsell R, et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007;195(1):125-31
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Nagano N, Urakawa I, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010;78(10):975-80
   PubMed Web of Science ®Google Scholar
• Craver L, Marco MP, Martinez I, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5–achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007;22(4):1171-6
   PubMed Web of Science ®Google Scholar
• Larsson T, Nisbeth U, Ljunggren O, et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64(6):2272-9
   PubMed Web of Science ®Google Scholar
• Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359(6):584-92
   PubMed Web of Science ®Google Scholar
• Xiao Y, Luo X, Huang W, et al. Fibroblast growth factor 23 and risk of all-cause mortality and cardiovascular events: a meta-analysis of prospective cohort studies. Int J Cardiol 2014;174(3):824-8
   PubMed Web of Science ®Google Scholar
• Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012;122(7):2543-53
   PubMed Web of Science ®Google Scholar
• Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121(11):4393-408
   PubMed Web of Science ®Google Scholar
• Xie J, Yoon J, An SW, et al. Soluble klotho protects against uremic cardiomyopathy independently of fibroblast growth factor 23 and phosphate. J Am Soc Nephrol 2015;26(5):1150-60
   PubMed Web of Science ®Google Scholar
• Agarwal I, Ide N, Ix JH, et al. Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc 2014;3(1):e000584
   Google Scholar
• Fuernau G, Poss J, Denks D, et al. Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Crit Care 2014;18(6):713
   PubMed Web of Science ®Google Scholar
• Saito Y, Yamagishi T, Nakamura T, et al. Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 1998;248(2):324-9
   PubMed Web of Science ®Google Scholar
• Silswal N, Touchberry CD, Daniel DR, et al. FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab 2014;307(5):E426-36
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Sonmez A, Saglam M, et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010;78(7):679-85
   PubMed Web of Science ®Google Scholar
• Ozkok A, Kekik C, Karahan GE, et al. FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients. BMC Nephrol 2013;14:241
   PubMed Web of Science ®Google Scholar
• Asicioglu E, Kahveci A, Arikan H, et al. Fibroblast growth factor-23 levels are associated with vascular calcifications in peritoneal dialysis patients. Nephron Clinical practice 2013;124(1-2):89-93
   PubMed Web of Science ®Google Scholar
• Scialla JJ, Lau WL, Reilly MP, et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int 2013;83(6):1159-68
   PubMed Web of Science ®Google Scholar
• Moldovan D, Moldovan I, Rusu C, et al. FGF-23, vascular calcification, and cardiovascular diseases in chronic hemodialysis patients. Int Urol Nephrol 2014;46(1):121-8
   PubMed Web of Science ®Google Scholar
• Seiler S, Rogacev KS, Roth HJ, et al. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin J Am Soc Nephrol 2014;9(6):1049-58
   PubMed Web of Science ®Google Scholar
• Voigt M, Fischer DC, Rimpau M, et al. Fibroblast growth factor (FGF)-23 and fetuin-A in calcified carotid atheroma. Histopathology 2010;56(6):775-88
   PubMed Web of Science ®Google Scholar